Andrea Lobo, PhD, science writer —

Mental health issues — namely, attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) — in children with cystic fibrosis (CF) may be associated with a poorer adherence to treatments, more hospitalizations, and higher use of antibiotics, according to a recent report. “These initial findings suggest that mental health screening…

Blood levels of an indicator of diabetes, glycated hemoglobin (HbA1c), fell within the first year that cystic fibrosis (CF) patients were treated with Kaftrio, the triple combination therapy marketed as Trikafta in North America, according to a study of patients in Denmark. But among those with CF-related…

Treatment with CFTR modulators lessened the need for opioids and other painkillers in people with cystic fibrosis (CF), and led to a more stable use of psychotropics among those being treated for their mental health, a real-world data study from Australia reported. These therapies also led to increases…

ViaNautis has secured $25 million in financing to advance work with polyNaut, its delivery platform for genetic and other treatments. The platform is designed to deliver a range of therapies into difficult-to-penetrate tissues. According to the company, the money raised will help to support polyNaut’s use…

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improved lung function and nutritional status in two adults with cystic fibrosis (CF) caused by the rare mutation M1101K, according to two cases described in Canada. “Our cases not only demonstrate the therapeutic benefit of [Trikafta] in individuals with non-F508del…

The pediatric and adult cystic fibrosis programs at Geisinger Medical Center have received an award from the Cystic Fibrosis Foundation (CFF) for their work in improving the care of people with cystic fibrosis (CF). Given annually, the CFF’s Quality Improvement Award recognizes centers that work continuously to improve…

Kaftrio and Symkevi — marketed in the U.S. as Trikafta and Symdeko, respectively — may be effective in treating people with cystic fibrosis (CF) caused by rare mutations, according to a new study from the U.K. Both treatments were found to improve lung function and to ease…

Treatment with Kaftrio eased gastrointestinal symptoms in people with cystic fibrosis (CF), ages 12 and older, according to a real-world study in the U.K and Ireland. The treatment’s maximum effect was achieved after two months and included a decline in gut inflammation. The study, “Reduction in abdominal…

Electronic home monitoring using a spirometry device may help improve lung function in children with cystic fibrosis (CF), according to a recent study. Specifically, a standard measure of lung function called forced expiratory volume in one second (FEV1) was found significantly improved in children who used the device, compared…

Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator of liver fibrosis — in adults with cystic fibrosis (CF), according to a recent study in the U.K. However, patients with elevated markers of liver stiffness before starting on…